MedPath

Drug-drug Interaction Study of Aripiprazole and Lamotrigine in Patients With Bipolar Type I Disorder

Phase 1
Completed
Conditions
Bipolar Disorder
Interventions
Registration Number
NCT00321516
Lead Sponsor
Otsuka Pharmaceutical Development & Commercialization, Inc.
Brief Summary

The purpose of this clinical research study is to learn if aripiprazole has a drug-drug interaction with lamotrigine.

Detailed Description

Not available

Recruitment & Eligibility

Status
COMPLETED
Sex
All
Target Recruitment
20
Inclusion Criteria
  • Body mass index (BMI) of 18 to 40 kg/m2
  • Subjects with bipolar I disorder who are clinically stable on a stable dose of at least 100 mg lamotrigine for at least 4 weeks prior to study entry
  • Men and women, ages 18 to 65
Exclusion Criteria
  • Women who are pregnant or breastfeeding
  • Patients with any significant acute or chronic medical illness, other than bipolar I disorder
  • Subjects with active psychotic symptoms
  • History of head trauma within the past 2 years
  • History of akathisia requiring treatment
  • History of tardive dyskinesia or abnormal involuntary movements
  • Subjects with a predisposition to orthostatic hypotension
  • Positive urine screen for drugs of abuse
  • Use of narcotic-containing agents, amphetamines, or hormonal contraceptives within 4 weeks of study start

Study & Design

Study Type
INTERVENTIONAL
Study Design
SINGLE_GROUP
Arm && Interventions
GroupInterventionDescription
1aripiprazole-
Primary Outcome Measures
NameTimeMethod
Comparison of Cmax (maximum drug concentration) and AUC(Tau) (exposure) of lamotrigine at the beginning of the study (Day-1) and when the subject completes the study (Day 36)
Secondary Outcome Measures
NameTimeMethod
Assess the safety and tolerability of aripiprazole when co-administered with lamotrigine for up to 4 weeks

Trial Locations

Locations (1)

Local Institution

🇺🇸

Desota, Texas, United States

© Copyright 2025. All Rights Reserved by MedPath